Toll-like receptor 4 gene polymorphisms show no association with the risk of clinical or angiographic restenosis after percutaneous coronary intervention
Authors:
- Marcel A.M. BeijkMBMarcel A.M. Beijk
- S. Matthijs BoekholdtSBS. Matthijs Boekholdt
- Saskia Z.H. RittersmaSRSaskia Z.H. Rittersma
- Douwe PonsDPDouwe Pons
- Aeilko H. ZwindermanAZAeilko H. Zwinderman
- Pieter A.F. DoevendansPDPieter A.F. Doevendans
- Rene A. TioRTRene A. Tio
- Jan G.P. TijssenJTJan G.P. Tijssen
- J. Wouter JukemaJJJ. Wouter Jukema
- Robbert J. de WinterRWRobbert J. de Winter
- 1 September 2010
- journal article
- Published by Wolters Kluwer Health in Pharmacogenetics and Genomics
- Vol. 20 (9) , 544-552
Abstract
Restenosis after percutaneous coronary intervention (PCI) remains an issue even in the drug-eluting stent era. Genetic polymorphisms may provide insight in the pathogenesis of restenosis and may help in the stratification of patients at risk for restenosis. The aim of this study was to examine whether polymorphisms at the toll-like receptor 4 (TLR4) locus, that are associated with impaired innate immune system and with an increased risk of cardiovascular events, were associated with clinical and/or angiographic restenosis after PCI. The GENetic Determinants of Restenosis (GENDER) project was a prospective, multicenter study that enrolled 3146 consecutive patients after successful PCI. Frequencies of the TLR4 896A/G (Asp299Gly; rs4986790) and 1196C/T (Thr399Ile; rs4986791) polymorphisms and haplotypes were assessed. Patients were followed up for 1 year and in a subgroup of 406 patients angiographic follow-up was obtained. We included a total of 2682 patients that underwent successful PCI. There was no association between genotypes and the risk of target vessel revascularization at 1-year or late luminal loss at 6-months angiographic follow-up (P=0.53 and 0.44, respectively). Absence of association with target lesion revascularization and late luminal loss was replicated in the GEnetic risk factors for In-Stent Hyperplasia study Amsterdam (GEISHA) cohort study of 674 patients and in a subgroup of 550 patients with angiographic follow-up available (P=0.26, and 0.86, respectively). Moreover, in both the studies, no significant differences between haplotypes A/C and G/T were observed for target vessel revascularization at late luminal loss. Although inflammation has been implicated in the pathophysiology of restenosis, the 896A/G and 1196C/T polymorphisms or haplotypes based on these polymorphisms at the TLR4 locus are not associated with an increased risk of target vessel revascularization or angiographic restenosis after PCI. These polymorphisms are not useful for pre-PCI identification of patients at risk for restenosis.Keywords
This publication has 34 references indexed in Scilit:
- Coronary-Artery StentsNew England Journal of Medicine, 2006
- Interindividual variation in the response by fibrinogen, C-reactive protein and interleukin-6 to yellow fever vaccinationBlood Coagulation & Fibrinolysis, 2004
- Genetic risk for restenosis after coronary balloon angioplastyAtherosclerosis, 2004
- The monocyte: the key in the lock to reduce stent hyperplasia?**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.JACC, 2004
- Are cytokine gene polymorphisms related to in vitro cytokine production profiles?Liver Transplantation, 2003
- Inflammation and Restenosis in the Stent EraArteriosclerosis, Thrombosis, and Vascular Biology, 2002
- Morphological Predictors of Restenosis After Coronary Stenting in HumansCirculation, 2002
- Cytokine gene polymorphism in human disease: on-line databases, Supplement 1Genes & Immunity, 2001
- Pathology of Acute and Chronic Coronary Stenting in HumansCirculation, 1999
- Neointimal Tissue Response at Sites of Coronary Stenting in HumansCirculation, 1998